|Bid||109.41 x 500|
|Ask||110.00 x 200|
|Day's Range||107.68 - 109.64|
|52 Week Range||94.55 - 147.17|
|PE Ratio (TTM)||25.64|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The FDA could further pressure generic drugmakers in 2018 by continuing along its path of increased generic approvals.
Presentations on potentially game-changing gene therapies were front and center at this year's American Society of Hematology conference.
Juno is now the cheapest CAR-T player, an analyst said Wednesday as he downgraded rival Bluebird on a lack of catalysts until the spring.
Shares of Intercept Pharmaceuticals (ICPT) are higher on Wednesday, following a bullish note from Deutsche Bank, which also initiated coverage on Celgene (CELG) and Regeneron (REGN). Analyst Navin Jacob ...
A next-generation cancer treatment could significantly change multiple myeloma outcomes for thousands of people, generating hundreds of millions of dollars in sales for the company.
The annual meeting of the American Society of Hematology was the key highlight this week with several companies like bluebird (BLUE) presenting data on their investigational treatments.
Juno (JUNO) releases additional results from the ongoing phase I study of its chimeric antigen receptor T-cell (CAR-T) therapy candidate, JCAR017.
bluebird (BIRD) announced updated results from the ongoing phase I study of its chimeric antigen receptor T-cell (CAR-T) therapy candidate- bb2121.
Data from LentiGlobin in sickle cell disease gives us confidence the mfr improvements could lead to increased efficacy, and we think a second SCD pt has achieved a functional cure. Elsewhere, Barclay's Gena Wang reiterated an Outperform rating and $162 price target on bluebird: Despite increasing competition with multiple BCMA data presented at the ASH over the weekend, BLUE’s bb2121 continued to show potentially best-in-class BCMA CAR-T asset in R/R multiple myeloma. Its superior safety and efficacy profile makes bb2121 feasible to move to earlier lines of therapy C a significantly larger market opportunity for CAR T therapy.
Several biotechnology stocks vaulted into double-digit gains after reporting clinical data on blood-disorder medications.
Shares of Bluebird Bio (BLUE) were up nearly 20% in early morning trading Monday as investors responded to the company's announcement that its CAR-T candidate, bb2121, produced encouraging results in patients with a deadly blood cancer.
The Zacks Analyst Blog Highlights: Bank of America, Celgene, Goldman Sachs, L Brands and Quest Diagnostics
Beleaguered biotech investors will likely have to wait until 2018 to get some much-needed relief, analysts say.
Sanofi (SNY) starts two new phase III studies evaluating isatuximab in combination with other cancer medicines for the treatment of multiple myeloma, a rare blood cancer.
Stocks are poised to climb on Friday following an upbeat jobs report. S&P 500 futures and Dow Jones Industrial futures are both up 0.3%, while Nasdaq futures are climbing 0.6%. As for specific stocks, ...
23 analysts were tracking Pfizer in November 2017. One analyst recommended a “strong buy,” while 11 analysts recommended a “buy.”